Lack of association of the CD14/C -159T polymorphism with susceptibility and progression parameters in Turkish multiple sclerosis patients

Journal of Neuroimmunology

Volumn 250, Issue 1-2, 2012, Pages 83-86

  Kurne, Asli ^a   Sayat, Guliz ^a   Aydin, Omer Faruk ^b   Turgutoglu, Nihan ^a   Terzi, Murat ^b   Sackesen, Cansin ^a   Karabulut, Erdem ^a   Karabudak, Rana ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

CD14 polymorphism; Multiple sclerosis; Progression index; RRMS; Soluble CD14

Indexed keywords

CD14 ANTIGEN;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIGENS, CD14; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TURKEY;

EID: 84864848432     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.05.005     Document Type: Article

References (19)

1. Baldini M., Lohman I.C., Halonen M., Erickson R.P., Holt P.G., Martinez F.D. A polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am. J. Respir. Cell Mol. Biol. 1999, 20:976-983.
2. Brettschneider J., Ecker D., Bitsch A., Bahner D., Bogumil T., Dressel A., Elitok E., Kitze B., Poser S., Weber F., Tumani H. The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b. J. Neuroimmunol. 2002, 133:193-197.
3. Cleveland M.G., Gorham J.D., Murphy T.L., Tuomanen E., Murphy K.M. Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. Infect. Immun. 1996, 64:1906-1912.
4. Duchow J., Marchant A., Crusiaux A., Husson C., Alonsovega C., Degroote D., Neve P., Goldman M. Impaired phagocyte responses to lipopolysaccharide in paroxysmal-nocturnal hemoglobinuria. Infect. Immun. 1993, 61:4280-4285.
5. Egerer K., Feist E., Rohr U., Pruss A., Burmester G.R., Dorner T. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 2000, 9:614-621.
6. Hubacek J.A., Pit'ha J., Skodova Z., Stanek V., Poledne R. C(-260)-> T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999, 99:3218-3220.
7. Jadidi-Niaragh F., Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand. J. Immunol. 2011, 74:1-13.
8. Kantarci O.H., de Andrade M., Weinshenker B.G. Identifying disease modifying genes in multiple sclerosis. J. Neuroimmunol. 2002, 123:144-159.
9. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
10. Lin J., Yao Y.M., Yu Y., Chai J.K., Huang Z.H., Dong N., Sheng Z.Y. Effects of CD14-159 C/T polymorphism on CD14 expression and the balance between proinflammatory and anti-inflammatory cytokines in whole blood culture. Shock 2007, 28:148-153.
11. Lutterotti A., Kuenz B., Gredler V., Khalil M., Ehling R., Gneiss C., Egg R., Deisenhammer F., Berger T., Reindl M. Increased serum levels of soluble CD14 indicate stable multiple sclerosis. J. Neuroimmunol. 2006, 181:145-149.
12. Medzhitov R., Janeway C. Innate immunity. N. Engl. J. Med. 2000, 343:338-344.
13. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., le Page E., Edan G., McDonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Sorensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sa M., Salemi G., Savettieri G., Hillert J., Compston D.A. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151.
14. Sackesen C., Karaaslan C., Keskin O., Tokol N., Tahan F., Civelek E. The effect of polymorphisms at the CD14 promoter and the TLR4 gene on asthma phenotypes in Turkish children with asthma. Allergy 2005, 60:1485-1492.
15. Sadovnick A.D. Genetic background of multiple sclerosis. Autoimmun. Rev. 2012 Jan, 11(3):163-166. 10.1016/j.autrev.2011.05.007.
16. Vrethem M., Kvarnström M., Stenstam J., Cassel P., Gustafsson M., Landtblom A., Ernerudh J. Cytokine mapping in cerebrospinal fluid and blood in multiple sclerosis patients without oligoclonal bands. Mult. Scler. 2012 May, 18(5):669-673. Epub 2011 Sep 30.
17. Walter S., Doering A., Letiembre M., Liu Y., Hao W., Diem R., Bernreuther C., Glatzel M., Engelhardt B., Fassbender K. The LPS receptor, CD14, in experimental autoimmune encephalomyelitis and multiple sclerosis. Cell. Physiol. Biochem. 2006, 17:167-172.
18. Weinshenker B.G. The natural history of multiple sclerosis. Neurol. Clin. 1995, 13:119-146.
19. Yen M.Y., Yen T.C., Pang C.Y., Liu J.H., Wei Y.H. Mitochondrial DNA mutation in Leber's hereditary optic neuropathy. Invest. Ophthalmol. Vis. Sci. 1992, 33:2561-2566.